Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUBBLE: Vedolizumab PK/Safety in Pediatric UC or CD
NCT03138655Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of vedolizumab in ulcerative colitis (UC) and Crohn's disease (8 arms), sponsored by Takeda. Primary endpoints: Area Under the Serum Concentration-time Curve at Week 14, Average Serum Concentration at Week 14 and 1 more. Started Nov 2017; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03138655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138655.